Cargando…

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

BACKGROUND: Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies (mAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ellen Q., Bukowski, Jack F., Yunis, Carla, Shear, Charles L., Ridker, Paul M., Schwartz, Pamela F., Baltrukonis, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790354/ https://www.ncbi.nlm.nih.gov/pubmed/31529318 http://dx.doi.org/10.1007/s40259-019-00375-0

Ejemplares similares

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
por: Yokote, Koutaro, et al.
Publicado: (2019)

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1
por: Chasman, Daniel I., et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
por: Gouni‐Berthold, Ioanna, et al.
Publicado: (2016)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

Development and Characterization of New Species Cross-Reactive Anti-Sialoadhesin Monoclonal Antibodies
por: De Schryver, Marjorie, et al.
Publicado: (2016)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Anti‐murine Antibody Response to Mouse Monoclonal Antibodies in Cancer Patients
por: Sakahara, Harumi, et al.
Publicado: (1997)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
por: Khoshnejad, Makan, et al.
Publicado: (2019)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies
por: Wilder, Brandon K., et al.
Publicado: (2022)

Preliminary Assessment of Various Additives on the Specific Reactivity of Anti- rHBsAg Monoclonal Antibodies
por: Yazdani, Yaghoub, et al.
Publicado: (2015)

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.
por: Ledermann, J. A., et al.
Publicado: (1988)

Monoclonal ant-idiotypic antibodies reactive with a highly conserved determinant on A/J serum anti-para-azophenylarsonate antibodies
Publicado: (1981)

Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial
por: Bass, Almasa, et al.
Publicado: (2018)

Humanization and Characterization of an Anti-Ricin Neutralization Monoclonal Antibody
por: Hu, Wei-Gang, et al.
Publicado: (2012)

Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)

Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies
por: Rahim, Md Niaz, et al.
Publicado: (2019)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Monoclonal antibody as a potential anti-COVID-19
por: Jahanshahlu, Leila, et al.
Publicado: (2020)

Anti-infective monoclonal antibodies: perils and promise of development
por: Reichert, Janice M., et al.
Publicado: (2006)

Preparation and identification of anti-rabies virus monoclonal antibodies
por: Wang, Wen-juan, et al.
Publicado: (2012)

A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.
por: Heyderman, E., et al.
Publicado: (1985)

Quantitative characterization of the mechanism of action and impact of a ‘proteolysis-permitting’ anti-PCSK9 antibody
por: Hansen, Ryan J., et al.
Publicado: (2016)

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer
por: Ito, Masaaki, et al.
Publicado: (2021)

Improvement of Anti-CD36 Antibody Detection via Monoclonal Antibody Immobilization of Platelet Antigens Assay by Using Selected Monoclonal Antibodies
por: Xu, Xiuzhang, et al.
Publicado: (2023)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0bvp4skcajconkghgp9n3lfkg0